Skip to content
Open access

Therapeutic drug monitoring of ustekinumab in Crohn’s disease patients: a real-world study

Oct 2026 · Pharmacia · Vol 73 · 0 citations · 30 references

TL;DR

Therapeutic drug monitoring of UST could serve as a valuable approach for optimizing CD therapy and recommendations were made to continue treatment in 43 patients, escalate therapy or shorten the dosing interval in 20 patients, and switch to another biologic agent in 13 patients.

Abstract

Crohn’s disease (CD) is a chronic inflammatory disorder. Ustekinumab (UST) is an effective treatment for CD. Therapeutic drug monitoring (TDM) enhances clinical efficacy while minimizing side effects. This study aimed to evaluate the UST trough level (TL) and anti-drug antibodies (ADAs) and to assess the response of patients with CD to optimize UST treatment. This single-center, cross-sectional study included 76 adult patients with CD receiving maintenance UST for at least 24 weeks. The serum TL of UST and clinical remission were assessed at the same visit, immediately before the next dose. Patients were categorized into two groups: Group A, patients reaching the UST target TL (≥1 µg/mL), and Group B, patients failing to reach it. The association between UST exposure and remission was assessed by binary logistic regression. The remission rate was significantly higher in Group A (78.2%) than in Group B (28.6%) ( p < 0.001). Based on the TL of UST, ADA positivity, and disease activity, recommendations were made to continue treatment in 43 patients, escalate therapy or shorten the dosing interval in 20 patients, and switch to another biologic agent in 13 patients. Accordingly, TDM of UST could serve as a valuable approach for optimizing CD therapy.

Read PDF

Similar papers

Open access Sep 2026

Early but not serial ustekinumab concentration measurements are associated with clinical outcomes in Crohn's disease and ulcerative colitis: the Stockholm Ustekinumab study (STOCUSTE).

INTRODUCTION Ustekinumab (UST), an anti-interleukin-12/23 antibody, is used to treat moderate-to-severe inflammatory bowel disease (IBD). The STOCUSTE study includes IBD patients treated with UST at four teaching hospitals in Stockholm to provide long-term follow-up data. The utility of therapeutic drug monitoring to o...

H. Sabhan, F. Bello, Samer Muhsen et al. · 0 citations
Open access Sep 2026

Towards Precision Medicine in Inflammatory Bowel Diseases: Pharmacogenetic Predictors of Ustekinumab Effectiveness and Persistence

IL12B rs6887695 emerged as a potential pharmacogenetic marker associated with favorable ustekinumab outcomes; however, this exploratory and hypothesis-generating finding requires external validation in larger, independent cohorts before clinical application.

Ylenia Marino, M. Rottura, Claudia Ligresti et al. · 0 citations
Open access Sep 2026

Dual-targeted therapy with ustekinumab and vedolizumab as a novel rescue strategy: achieving high clinical response rates in Crohn's disease refractory to both monotherapies.

BACKGROUND Managing Crohn's disease is challenging as a substantial proportion of patients lose response to biologics. This study evaluated dual targeted therapy (DTT) with ustekinumab (UST) and vedolizumab (VDZ) in patients refractory to both agents as monotherapies. METHODS This retrospective study enrolled 23 pati...

Chong Lu, Tao Ling, Ya-Fang Li et al. · 0 citations
Open access Oct 2026

Prior Ustekinumab Exposure and Ulcerative Colitis Are Associated with Suboptimal Trough Levels in Patients Receiving Advanced-Line Vedolizumab or Ustekinumab for Inflammatory Bowel Disease: A Cross-Sectional Cohort Study

Background: Ustekinumab (UST) and vedolizumab (VDZ) are established therapies for Crohn’s disease (CD) and ulcerative colitis (UC), including in patients with prior tumour necrosis factor-alpha inhibitor (anti-TNF) failure. Trough levels (TRLs) and antidrug antibodies (ADAs) are among several factors associated with th...

Petra Nagypál, Krisztián A. Kovács, Barna Vásárhelyi et al. · 0 citations
Open access Sep 2026

Retrospective analysis of ustekinumab in Crohn’s disease between biologic-naïve and biologic-experienced

Objective This thesis investigates the differences in clinical efficacy of ustekinumab (UST) as a biologic-naïve or biologic-experienced for Crohn’s Disease (CD) patients in terms of clinical manifestations and laboratory test indicators. It also explores the correlation between clinical response status and patients’ q...

K. Yuan, Xian-Hong Hu, Qiong-Xuan Fang et al. · 0 citations
Open access Sep 2026

Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).

Upadacitinib was effective and well-tolerated in AT-experienced Crohn's disease, including patients with active EIMs, with induction benefit maintained through 6 months without novel safety signals.

B. Barberio, F. D'Amico, L. Laterza et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.